Pharmaceutical

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

Jun 28, 2024 - 04:00
FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market
Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.
Read the original article

Tags:

Previous Article

Biotech fund Curie.Bio augments reserves with $380m to boost startups  

Next Article

Formation Bio secures $372m funds for AI-driven drug platform

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Novo Nordisk stops trial of Ozempic in kidneys as interim analysis shows success

Novo Nordisk stops trial of Ozempic in kidneys as inter...

Oct 17, 2023

ASCO 2024: J&J’s early radioligand prostate cancer trial reports four patient deaths

ASCO 2024: J&J’s early radioligand prostate cancer tria...

May 29, 2024

Johnson & Johnson antiviral pill for dengue shows early efficacy

Johnson & Johnson antiviral pill for dengue shows early...

Oct 24, 2023